Bevacizumab

Bevacizumab Properties

storage temp.	Store at -80°C
solubility	Soluble in DMSO
NCI Dictionary of Cancer Terms	Avastin; bevacizumab
FDA UNII	2S9ZZM9Q9V
NCI Drug Dictionary	Avastin
ATC code	L01XC07
Proposition 65 List	Bevacizumab

Pharmacokinetic data

Volume of distribution	0.046(L/kg)
Biological half-life	11-50 days (average 20 days) / -

Bevacizumab price

Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
Sigma-Aldrich	1445547	USP mAb 002, Monoclonal IgG1 United States Pharmacopeia (USP) Reference Standard	216974-75-3	2MG	$1370	2024-03-01	Buy
Biosynth Carbosynth	FB76708	Bevacizumab - 25mg/ml solution in PBS	216974-75-3	25mg	$1875	2021-12-16	Buy
ChemScene	CS-7820	Bevacizumab ≥99.0%	216974-75-3	25mg	$2500	2021-12-16	Buy
ChemScene	CS-7820	Bevacizumab ≥99.0%	216974-75-3	50mg	$4000	2021-12-16	Buy
Biosynth Carbosynth	FB76708	Bevacizumab - 25mg/ml solution in PBS	216974-75-3	1mg	$150	2021-12-16	Buy

Product number	Packaging	Price	Buy
1445547	2MG	$1370	Buy
FB76708	25mg	$1875	Buy
CS-7820	25mg	$2500	Buy
CS-7820	50mg	$4000	Buy
FB76708	1mg	$150	Buy

Bevacizumab Chemical Properties,Uses,Production

Description

Bevacizumab, a humanized IgG1 monoclonal antibody against vascular endothelial growth factor (VEGF), inhibits tumor angiogenesis and delays disease progression. It was launched in the US as an intravenous infusion for the treatment of metastatic colorectal cancer in combination with fluorouracil-based chemotherapy. Bevacizumab was developed by engineering the VEGF binding residues of the murine neutralizing antibody A.4.6.1 into the framework of the consensus human IgG1. Its amino acid sequence is approximately 93% human IgG and 7% murine antibody and is produced in a CHO cell expression system. Bevacizumab binds VEGF with high affinity (K_d=0.5 nM) and prevents its interaction with tyrosine kinase receptors VEGFR1 and VEGFR2 on the surface of endothelial cells, thereby inhibiting cell proliferation and microvascular growth. In mouse models, administration of bevacizumab blocked the growth of human tumor xenografts and reduced the size and number of metastases. The recommended dosage of bevacizumab is 5 mg/kg administered once every 2 weeks as an intravenous infusion until disease progression is detected. Based on a population pharmacokinetic analysis of patients who received 1–20 mg/kg of bevacizumab once every 1–3 weeks, the estimated half-life was approximately 20 days, and the predicted time to reach steady state was 100 days. The maximum and minimum steady-state serum concentrations at 2.5 mg/kg/week dose were 226 and 88 μg/mL, respectively. Clearance of bevacizumab is low, and varies with body weight, gender and tumor burden. In patients with colorectal cancer receiving bevacizumab 5–10 mg/kg in combination with fluorouracil and leucovorin, mean total clearance was 2.79 ml/kg/day. In clinical studies involving the administration of bevacizumab (5 mg/kg every 2 weeks) or placebo in addition to bolus-IFL (irinotecan 125 mg/m² i.v., 5-fluorouracil 500 mg/ m² i.v., and leucovorin 20 mg/m² i.v. administered once weekly for four weeks every six weeks), the median overall survival was significantly increased from 15.6 months in the bolus IFL + placebo arm to 20.3 months in the bolus IFL + bevacizumab arm. Similar increases were also seen in progression-free survival (6.4 versus 10.6 months), overall response rate (35% versus 45%), and duration of response (7.1 months versus 10.4 months). The most common adverse events in these trials were hypertension, diarrhea and leucopenia. Other clinically significant adverse events reported occasionally were gastrointestinal perforations, thromboembolic events, bleeding and proteinuria. Because wound healing may be impaired by inhibition of VEGF, bevacizumab therapy is not recommended until 28 days after primary surgery.

Originator

Genentech (US)

brand name

Avastin

Clinical Use

Monoclonal antibody:

Treatment of colorectal cancer

Treatment of breast cancer

Treatment of renal cell carcinoma

Treatment of lung cancer

Treatment of ovarian, fallopian tube or peritoneal cancer

Enzyme inhibitor

This humanized monoclonal antibody (MW = 149.2 kDa; CAS 216974-75- 3), known by the tradename Avastinò, is an angiogenesis inhibitor that targets vascular endothelial growth factor A (VEGF-A). Because VEGF is the key angiogenic factor in tumors, blocking VEGF signal transduction can lead to tumor growth arrest and inhibition of metastasis. The rationale for Avastin therapy is premised on findings that high VEGF expression correlates with (a) reduced overall survival, (b) disease progression, (c) greater risk of relapse, (d) lymph node involvement, and (e) malignant pleural effusion. By binding directly bind to VEGF-A, Avastin blocks its interaction with endothelial cell VEGF receptors, thereby inhibiting neovascularization and depriving cancer cells of vital nutrients and oxygen. Avastin is approved for: metastatic colorectal cancer (mCRC), when started with the first or second intravenous 5-FU–based chemotherapy for metastatic cancer; advanced-stage nonsquamous, non–small cell lung cancer (NSCLC), when administered in combination with carboplatin and paclitaxel in patients who have not received chemotherapy for their advanced disease; metastatic renal cell cancer (mRCC) when used with interferon-a; and glioblastoma multiforme (GBM) in adult patients whose cancer has progressed after prior treatment.

target

Angiogenesis is important for tumour growth and metastasis, and is an important target for new biological agents. Bevacizumab is a humanised recombinant antibody that prevents vascular endothelial growth factor (VEGF) receptor binding, and inhibits angiogenesis and tumour growth.

Drug interactions

Potentially hazardous interactions with other drugs
Bisphosphonates: increased risk of osteonecrosis of the jaw.
Cytotoxics: avoid with panitumumab.
Vaccines: risk of generalised infections with live vaccines - avoid.

Metabolism

Assessment of bevacizumab metabolism in rabbits following a single IV dose of 125I-bevacizumab indicated that its metabolic profile was similar to that expected for a native IgG molecule which does not bind VEGF. The metabolism and elimination of bevacizumab is similar to endogenous IgG i.e. primarily via proteolytic catabolism throughout the body, including endothelial cells, and does not rely primarily on elimination through the kidneys and liver. Binding of the IgG to the FcRn receptor results in protection from cellular metabolism and the long terminal half-life.

Bevacizumab Preparation Products And Raw materials

Raw materials

Preparation Products

Bevacizumab Suppliers

Global( 134)Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
Shanghai Minbiotech Co., Ltd.	+8617315815539	sales@minbiotech.com	CHINA	129	58
Biochempartner	0086-13720134139	candy@biochempartner.com	CHINA	967	58
Shenzhen Nexconn Pharmatechs Ltd	+86-755-89396905 +86-15013857715	admin@nexconn.com	China	10248	58
Hubei xin bonus chemical co. LTD	86-13657291602	linda@hubeijusheng.com	CHINA	22968	58
Hubei Ipure Biology Co., Ltd	+8613367258412	ada@ipurechemical.com	China	10326	58
HONG KONG IPURE BIOLOGY CO.,LIMITED	86 18062405514 18062405514	ada@ipurechemical.com	CHINA	3465	58
Shaanxi Dideu Medichem Co. Ltd	+86-029-89586680 +86-18192503167	1026@dideu.com	China	9271	58
Dideu Industries Group Limited	+86-29-89586680 +86-15129568250	1026@dideu.com	China	29118	58
AFINE CHEMICALS LIMITED	0571-85134551	info@afinechem.com	CHINA	15377	58
Wuhan Fortuna Chemical Co., Ltd	+86-27-59207850 +86-13986145403	info@fortunachem.com	China	5988	58

Supplier	Advantage
Shanghai Minbiotech Co., Ltd.	58
Biochempartner	58
Shenzhen Nexconn Pharmatechs Ltd	58
Hubei xin bonus chemical co. LTD	58
Hubei Ipure Biology Co., Ltd	58
HONG KONG IPURE BIOLOGY CO.,LIMITED	58
Shaanxi Dideu Medichem Co. Ltd	58
Dideu Industries Group Limited	58
AFINE CHEMICALS LIMITED	58
Wuhan Fortuna Chemical Co., Ltd	58

View Lastest Price from Bevacizumab manufacturers

Update time	Product	Price	Min. Order	Purity	Supply Ability	Manufacturer
2023-02-07	Bevacizumab 216974-75-3	US $0.00 / G	1G	98%min	30kg/month	WUHAN FORTUNA CHEMICAL CO., LTD
2021-09-16	Bevacizumab 216974-75-3	US $0.00-0.00 / mg	1mg	99%	100KG	Hangzhou Huarong Pharm Co., Ltd.
2021-06-05	Bevacizumab USP/EP/BP 216974-75-3	US $1.10 / g	1g	99.9%	100 Tons Min	Dideu Industries Group Limited

Bevacizumab
216974-75-3
US $0.00 / G
98%min
WUHAN FORTUNA CHEMICAL CO., LTD

Bevacizumab
216974-75-3
US $0.00-0.00 / mg
99%
Hangzhou Huarong Pharm Co., Ltd.

Bevacizumab USP/EP/BP
216974-75-3
US $1.10 / g
99.9%
Dideu Industries Group Limited

216974-75-3(Bevacizumab)Related Search:

Adalimumab Ustekinumab Nivolumab Daratumumab OMALIZUMAB

Lambrolizumab Dulaglutide Infliximab Rituximab Gemcitabine

Hydroxyl camptothecine Triamcinolone acetonide Icotinib Ranibizumab Evolocumab

Ramucirumab ipilimumab Eculizumab

1of4

BevacizuMab [USAN:INN] Anti-vegf monoclonal antibody Bevacizumab Immunoglobulin G1, anti-(human vascular endothelial growth factor) (human-mouse monoclonal rhumab-vegf gamma1-chain), disulfide with human-mouse monoclonal rhumab-vegf light chain, dimer Rhumab-vegf Unii-2S9zzm9Q9v Avastatin Bevacituzumab Bevacizumab (Avastin) Bevacizumab - 25mg/ml solution in PBS Bevacizumab(anti-VEGF) Bevacizumab USP/EP/BP Avastin Research Grade Bevacizumab(DHD12602) Bevacizumab, Lyophilized powder USP mAb 002, Monoclonal IgG1 (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) Bevacizumab Impurity 216974-75-3 C6638H10160N1720O2108S44